The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
one big problem we have right now in adjuvant therapy in places like many places but you know breast cancer is a good example of it we treat the number need to treat is quite high because most patients don't already care about the surgeon and don't have micromanage diet disease and then the treatments aren't perfect so the ones even though that have micrometeoroid diseases infinite number don't benefit so uh actually we have a huge problem with overtreatment
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.